Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Contact Energy, Geo40 partner with Maori on world-leading energy project

2018-07-19 nzherald.co.nz
Geo40, Contact Energy and the Ngati Tahu Tribal Lands Trust are teaming up as part of a world-leading sustainable energy project.
CEN COENF CEN COENY

0
Farmlands takes honours in survey of Kiwi brands

2018-07-12 nbr.co.nz
The Farmlands Co-operative Society has emerged as the top New Zealand brand in a KPMG survey that asked customers of different countries to rate brands on various criteria related to customer experience.
CEN FBU AIR FCREY FRCEF ANZFY COENY AIZ COENF FBU ANZLY CEN ANZFF

0
60 leading Kiwi CEOs commit to climate action

2018-07-11 nzherald.co.nz
Bosses of 60 companies that make up nearly half of New Zealand's greenhouse gas emissions have pledged to take a fresh stand on climate change.
CEN AIR ZNRGF WHGPF ZEL ANZFY COENY AIZ WHS COENF ZNZ WHOSY ANZLY CEN ANZFF

18
Fran O'Sullivan: Boardroom shuffle as Fletcher Building works to rebuild

2018-06-22 nzherald.co.nz
The shakeout of the Fletcher Building board is proceeding at a gentlemanly pace which will preserve exiting directors' reputations (as much as is possible) after one of the most disastrous episodes in recent corporate history.
CEN FBU AIR FCREY FRCEF ANZFY COENY AIZ COENF GNE FBU THL ANZLY CEN ANZFF GNE GEL

20
Fletcher Building appoints new chairman

2018-06-21 radionz.co.nz
Bruce Hassall has been appointed the new chairman of Fletcher Building to replace Sir Ralph Norris.
CEN FBU AIR FCREY NAB NASXF NABZY FRCEF ANZFY COENY AIZ COENF NAUBF GNE FBU THL ANZLY CEN ANZFF GNE GEL

14
Ex-PwC boss Bruce Hassall appointed Fletcher chairman

2018-06-21 nbr.co.nz
Fletcher Building has appointed the former PwC chief executive Bruce Hassall as chairman, replacing Sir Ralph Norris when he steps down in September.
CEN FBU AIR FCREY FRCEF ANZFY COENY AIZ COENF FBU ANZLY CEN ANZFF

13
Shares drop 1.2%, led by Pushpay and Mercury

2018-06-19 nzherald.co.nz
New Zealand shares dropped in broad-based selling, led lower by Pushpay Holdings following its $100 million bookbuild, with Mercury New Zealand and Fletcher Building also weakening.
CEN FBU FCREY SPKKY NZTCY SPK NZTCF FRCEF COENY COENF PPSHY FBU CEN

14
Sir Ralph Norris retires from Contact board

2018-06-14 nbr.co.nz
Boardroom heavyweight Sir Ralph Norris has resigned as chairman and director of Contact Energy in a move that will leave him with no significant board seats by the end of the year.
CEN FBU AIR FCREY FRCEF ANZFY COENY AIZ COENF FBU ANZLY CEN ANZFF

9
Rob McDonald to replace Ralph Norris as Contact Energy board chair

2018-06-14 nzherald.co.nz
Contact Energy chair Ralph Norris is stepping down from the board of New Zealand's largest electricity retailer having overseen a board refresh following the departure of majority owner Origin Energy.
CEN COENF ANZLY AIR CEN ANZFF OGFGF ANZFY COENY AIZ OGFGY ORG

14
Shares fall in light trading after index reweighting

2018-06-01 nzherald.co.nz
New Zealand shares fell in more subdued trading following yesterday's billion-dollar MSCI rebalancing, with A2 Milk Co and Synlait dropping while Air New Zealand gained.
CEN AIR ZNRGF ZEL ANZFY COENY AIZ COENF ZNZ ANZLY CEN ANZFF MEZ SML

2
Businesses 'should pay a fair price' for power - aluminium smelter

2018-05-31 radionz.co.nz
The financial position of the Tiwai Point aluminium smelter has improved to its best level in years, but it has renewed its criticism of the high cost of power.
CEN COENF CEN COENY

14
A2 Milk drops 3 per cent as sharemarket edges lower

2018-05-22 nzherald.co.nz
New Zealand shares fell, led lower by continued selling in A2 Milk Co and Comvita, while Ryman Healthcare and Heartland Bank gained.
KTHDY CEN NMR RHCGF RYM COENY KMD COENF AOTUF 8604 SKC AFP N33 RYHTY NRSCF CEN KMD

34
Shares rise as investors second guess index changes; Fletcher gains

2018-05-08 nzherald.co.nz
New Zealand shares rose, joining a regional rally, as investors predict whether an upcoming MSCI index review will spur major activity next week. Fletcher Building, which could exit the index, gains, while new addition a2 Milk Co fell.
CEN TME TRMEF PYIYY AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ KMD COENF TME CEN KMD KTHDY AIA FBU WBC SPKKY NZTCY SPK WEBNF WBK FRCEF COENY AIA WBC FBU ANZLY MPP MTPGF ANZFF TDMEY MEZ PFI

30
NZ shares up as A2 leads index

2018-05-02 nzherald.co.nz
New Zealand shares gained, with Gentrack Group hitting a record and electricity companies Mercury New Zealand and Contact Energy gaining.
CEN FCREY NZTCF RYM KMD COENF GNE AOTUF CEN KMD GEL KTHDY FBU WBC RHCGF SPKKY NZTCY SPK WEBNF WBK FRCEF COENY WBC FBU RYHTY GNE GTK MEZ

16
NZ shares dip; Kiwi Property, Fletcher drop

2018-05-01 nzherald.co.nz
New Zealand shares fell slightly, despite a gain in energy stocks and ANZ Bank New Zealand rising on its first-half earnings.
CEN FBU FCREY ZNRGF FRCEF ZEL COENY COENF SKT ZNZ GNE SYKWF SKC FBU CEN SKKTY GNE GTK MEZ GEL

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 21073R108